布塞脂酶(Bucelipase alfa) - 药物靶点：CEL_专利_临床

概要

基本信息

药物类型

酶

别名

BSSL、Bile salt stimulated lipase、Exinalda

+ [3]

靶点

CEL

作用机制

CEL刺激剂(carboxyl ester lipase stimulants)、脂肪酶替代物

治疗领域

遗传病与畸形消化系统疾病内分泌与代谢疾病+ [3]

在研适应症-

非在研适应症

囊性纤维化胰腺外分泌功能不全胎儿生长受限+ [3]

原研机构

AstraZeneca PLC

在研机构-

非在研机构

Swedish Orphan Biovitrum AB

Sobi Analytics Ltd.PPL Therapeutics Plc

+ [1]

最高研发阶段终止临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

序列信息

Sequence Code 192721

来源: *****

关联

7

项与布塞脂酶相关的临床试验

EUCTR2010-023909-35-HU / Not yet recruitingN/A

A Prospective, Randomized, Double-Blind, Phase 3 Study Comparing rhBSSL and Placebo Added to Infant Formula or Pasteurized Breast Milk During 4 Weeks of Treatment in Preterm Infants Born Before Week 32 of Gestational Age - BVT.BSSL-030

开始日期2011-06-20

申办/合作机构

Swedish Orphan Biovitrum AB

NCT01413581 / Terminated临床3期

A Prospective, Randomized, Double-Blind, Phase 3 Study Comparing rhBSSL and Placebo Added to Infant Formula or Pasteurized Breast Milk During 4 Weeks of Treatment in Preterm Infants Born Before Week 32 of Gestational Age

The purpose of this study is to demonstrate that rhBSSL improves growth in preterm infants as compared with placebo.

开始日期2011-05-01

申办/合作机构

Swedish Orphan Biovitrum AB

EUCTR2007-002434-10-IT / Not yet recruitingN/A

A prospective, randomised, double-blind crossover study comparing 0.15 g/L rhBSSL added to pasteurized breast milk versus placebo during one week of treatment in preterm infants born before week 32 of gestational age - ND

开始日期2008-09-25

申办/合作机构

Swedish Orphan Biovitrum AB

100 项与布塞脂酶相关的临床结果

登录后查看更多信息

100 项与布塞脂酶相关的转化医学

登录后查看更多信息

100 项与布塞脂酶相关的专利（医药）

登录后查看更多信息

69

项与布塞脂酶相关的文献（医药）

2024-10-01·Veterinary Parasitology

Effect of feeding a blackseed meal-sericea lespedeza leaf meal pellet on gastrointestinal nematode and coccidia infection and animal performance in young goats

Article

作者: Brown, D ; Smith, Y ; Shaik, A ; Miller, J E ; Erukulla, T ; Chelkapally, S C ; Siddique, A ; Whitley, N C ; Mendez, N ; Dykes, G S ; Kannan, G ; Neha, A ; Pech-Cervantes, A A ; Namani, S C ; Terrill, T H ; Owen, V R ; Kolikapongu, R S ; Batchu, P

Gastrointestinal nematode (GIN) infection poses the most significant obstacle to the sustainable development of small ruminant (sheep and goat) farming globally. Resistance of GINs to synthetic anthelmintic drugs has led to rising interest in exploring alternative methods for parasite control, such as the utilization of bioactive plants with anti-parasitic properties. In this investigation, black seed (Nigella sativa), a shrub high in secondary antioxidant compounds, and sericea lespedeza (Lespedeza cuneata), a perennial legume high in tannins with anti-parasitic properties were combined to determine if two bioactive plants containing different types of secondary compounds can provide a stronger anti-parasitic effect than sericea lespedeza alone. In a 49-day trial, naturally parasitized 6-7-month-old intact male Spanish goats (n = 15/treatment) were fed pelletized feeds encompassing sericea lespedeza leaf meal (SL), a combination of black seed meal (BS) and sericea lespedeza leaf meal (BS-SL - 75 % SL, 25 % BS), or alfalfa (Medicago sativa, control parasitized; CONP), with an additional group of dewormed kids given the alfalfa pellets (Control treated; CONT). Weekly measurements of animal weights and samples of blood and feces were collected to determine the packed cell volume (PCV), GIN fecal egg counts (FEC), and coccidia fecal oocyte counts (FOC), respectively. All animals were processed at the end of the trial (60 total), with adult Haemonchus contortus worms recovered from the abomasum of each goat for counting and sex determination. Carcass weights were recorded after processing. Goats given the SL and BS-SL treatments had lower FEC (P<0.05) than the parasitized alfalfa (CONP) goats. At the end of the study, the SL and BS-SL groups' FOC values were lower (P < 0.05) than the CONT and CONP groups. A rise in PCV values was seen over time for all groups; SL, BS-SL, and CONT animals exhibited higher PCV values (P < 0.05) in comparison to the CONP goats. The parasitized goats fed SL-only pellets showed greater feed intake and animal body weights (P < 0.05) compared to goats fed BS-SL or alfalfa pellets. However, the treatments had no effect on the weight of the goats' carcasses. Although the H. contortus adult worm counts in the CONT goats (alfalfa-dewormed) were lower (P < 0.05) than in the CONP goats (alfalfa-parasitized), they did not differ from the SL or BS-SL animals. This study indicates that sericea lespedeza leaf meal pellet diet, either by itself or in combination with black seed meal, showed promising results as an anthelmintic and may prove to be an effective alternative to exclusive use of conventional deworming drugs. The addition of black seed did not appear to enhance the effectiveness of sericea lespedeza in this study.

2024-06-19·ACS Nanoscience Au

Enhancing the Therapeutic Efficacy of GLP-1 for Hyperglycemia Treatment: Overcoming Barriers of Oral Gene Therapy with Taurocholic Acid-Conjugated Protamine Sulfate and Calcium Phosphate

Article

作者: An, Jeong Man ; Lee, Yong-kyu ; Surwase, Sachin S. ; Shahriar, S. M. Shatil ; Lee, Dong Yun

Activating the glucagon-like peptide-1 (GLP-1) receptor by oral nucleic acid delivery would be a promising treatment strategy against hyperglycemia due to its various therapeutic actions. However, GLP-1 receptor agonists are effective only in subcutaneous injections because they face multiple barriers due to harsh gastrointestinal tract (GIT) conditions before reaching the site of action. The apical sodium bile acid transporter (ASBT) pathway at the intestinal site could be an attractive target to overcome the problem. Herein, we used our previously established multimodal carrier system utilizing bile salt, protamine sulfate, and calcium phosphate as excipients (PTCA) and the GLP-1 gene as an active ingredient (GENE) to test the effects of different formulation doses against diabetes and obesity. The carrier system demonstrated the ability to protect the GLP-1 model gene encoded within the plasmid at the GIT and transport it via ASBT at the target site. A single oral dose, regardless of quantity, showed the generation of GLP-1 and insulin from the body and maintained the normoglycemic condition by improving insulin sensitivity and blood sugar tolerance for a prolonged period. This oral gene therapy approach shows significantly higher therapeutic efficacy in preclinical studies than currently available US Food and Drug Administration-approved GLP-1 receptor agonists such as semaglutide and liraglutide. Also, a single oral dose of GENE/PTCA is more effective than 20 insulin injections. Our study suggests that oral GENE/PTCA formulation could be a promising alternative to injection-based therapeutics for diabetics, which is effective in long-term treatment and has been found to be highly safe in all aspects of toxicology.

2024-03-25·Cureus

Odevixibat: A Novel Bile Salt Inhibitor Treatment for Pruritus in Progressive Familial Intrahepatic Cholestasis

Review

作者: Lockett, Stewart J ; Varrassi, Giustino ; Shekoohi, Sahar ; Mosieri, Chizoba N ; Flattmann, Farrah E ; Singh, Anjuni ; Kaye, Alan D ; Mohiuddin, Farhan S ; Tandon, Anamika ; Kaye, Adam M ; Hirsch, Jon D ; Ahmadzadeh, Shahab

Chronic pruritus is defined as an itch lasting greater than six weeks. It can manifest from a wide variety of etiologies, as many different substances can act as pruritogens, such as steroids, histamine, progesterone, endogenous opioids, and serotonin. In the setting of cholestatic liver disease, increased bile acids play a major role in chronic pruritus. The itching in cholestatic liver disease is worsened in intensity at night and localized frequently to the palms, soles, knees, and other pressure sites. It can be hard to manage, affecting the quality of sleep and causing irritability, poor attention, and, in some cases, depression. One such disease that results from chronic pruritus is progressive familial intrahepatic cholestasis (PFIC), a group of uncommon hereditary disorders that affects the formation of bile and its outflow from the liver. Previously, the drug ursodeoxycholic acid was used to help manage pruritus or surgical procedures, e.g., partial external biliary diversion or partial internal biliary diversion, to help control complications of the disease. This literature review will discuss three clinical studies covering the effectiveness of odevixibat in treating pruritus in patients with PFIC. Odevixibat (Bylvay) is an oral drug that has been FDA-approved to treat pruritus in patients three months of age and older with PFIC. Odevixibat prevents the reabsorption of bile salts in the intestines, resulting in decreased levels of bile salts via their excretion in stool. Several studies have determined that the drug is well tolerated and provides a nonsurgical, pharmacological treatment alternative for those with PFIC.

100 项与布塞脂酶相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
吸收不良综合征	临床3期	匈牙利	Swedish Orphan Biovitrum AB	-
吸收不良综合征	临床3期	-	Sobi Analytics Ltd.	-
吸收不良综合征	临床3期	丹麦	Swedish Orphan Biovitrum AB	-
吸收不良综合征	临床3期	西班牙	Swedish Orphan Biovitrum AB	-
吸收不良综合征	临床3期	意大利	Swedish Orphan Biovitrum AB	-
吸收不良综合征	临床3期	比利时	Swedish Orphan Biovitrum AB	-
吸收不良综合征	临床3期	捷克	Swedish Orphan Biovitrum AB	-
吸收不良综合征	临床3期	俄罗斯	Swedish Orphan Biovitrum AB	-
吸收不良综合征	临床3期	法国	Swedish Orphan Biovitrum AB	-
吸收不良综合征	临床3期	英国	Swedish Orphan Biovitrum AB	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01413581 \| NCT00659243 \| NCT00658905 (Pubmed \| J Pediatr Gastroenterol Nutr)	N/A	早产儿疾病	-	rhBSSL	(衊構憲觸餘網憲鹹鑰齋) = 獵衊夢壓積衊製夢鏇鹽廠網醖鑰鹽製製糧遞衊 (簾餘憲鏇網廠廠鑰範醖 ) 更多	积极	2014-07-01
				Placebo	(鑰積衊淵齋窪構鑰餘築) = 衊觸鬱顧夢製選製襯積顧顧齋鏇鏇網鏇顧醖夢 (願選夢鹽顧壓觸淵壓糧 ) 更多